Renascience Inc. Financial Summary for the Second Quarter (Interim) of Fiscal Year Ending March 2027

Business Performance Summary

Renascience Inc. announced its second quarter financial summary. Interim period revenue was 10 million yen, operating loss was 161,406 thousand yen, ordinary loss was 154,495 thousand yen, and interim net loss was 154,997 thousand yen. Research and development expenses amounted to 76,282 thousand yen, mainly due to continued investment in oncology, anti-aging areas, and development of AI program medical devices. Cash and cash equivalents were 3,193,623 thousand yen, net assets were 3,167,679 thousand yen, and the equity ratio remained at a high level. The company has made no changes to previously announced forward-looking estimates.

Outlook and Strategy

The company will continue a portfolio strategy utilizing multiple modalities. Clinical trials, including earlier- and later-stage studies for RS5614 in the oncology field, are progressing. Research and development in anti-aging and longevity areas will continue, and efforts to implement AI program medical devices in society will be advanced. The company plans to expand clinical trial progress and future business opportunities through international collaborative research and AMED grants. No changes to capital policy have been disclosed, but continued R&D investment will affect the financial position.